Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12094663 | 1.00 | HTR2C (0.55) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL25125018 | 0.89 | HTR2C (0.61) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL16237027 | 0.87 | HTR2C (0.51) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL30655538 | 0.87 | HTR2C (0.65) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL31346956 | 0.87 | HTR2C (0.53) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL21960132 | 0.87 | HTR2C (0.53) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL28647695 | 0.85 | HTR2C (0.49) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL28657850 | 0.85 | HTR2C (0.49) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL14336080 | 0.85 | HTR2C (0.57) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL16707782 | 0.85 | HTR2C (0.51) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120203004-A1 | PROCESS FOR THE SYNTHESIS OF ALKYL/ARALKYL (2S)-2-(TERT-BUTOXYCARBONYL)-AMINO-2-[-8-AZABICYCLO[3.2.1]OCT-3-YL]-EXO-ACETATE AND ANALOGS THEREOF: KEY INTERMEDIATES FOR THE PREPARATION OF DPPIV INHIBITORS | LUPIN LIMITED (IN) | 2012-08-09 | — | — | US | claimed |
| WO-2011018796-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF ALKYL/ARALKYL (2S)-2-(TERT-BUTOXYCARBONYL)-AMINO-2-[-8-AZABICYCLO[3.2.1]OCT-3-YL]-EXO-ACETATE AND ANALOGS THEREOF: KEY INTERMEDIATES FOR THE PREPARATION OF DPPIV INHIBITORS | LUPIN LIMITED (IN) | 2011-02-17 | — | — | WO | claimed |
| US-12319698-B2 | Proteasome activity enhancing compounds | Kineta, Inc. (US) | 2025-06-03 | — | — | US | disclosed |
| WO-2025110815-A1 | IMIDAZO [1,2-B] PYRIDAZINE-BASED NOVEL COMPOUND AS CDK INHIBITOR AND USE THEREOF | 아이리드비엠에스 주식회사 | 2025-05-30 | — | — | WO | disclosed |
| US-20240285611-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-11993591-B2 | Chromen-4-one derivatives for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2024-05-28 | — | — | US | disclosed |
| EP-3521289-B1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-116354932-A | Pyrimidine derivative, preparation method and application thereof | 海思科医药集团股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | YUMANITY THERAPEUTICS, INC. | 2023-06-15 | — | — | US | disclosed |
| WO-2007100670-A1 | SPIRO CONDENSED PIPERIDNES AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1817036-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007076070-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070043023-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20070043023-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20060270653-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-11-30 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006058303-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120203004-A1 | PROCESS FOR THE SYNTHESIS OF ALKYL/ARALKYL (2S)-2-(TERT-BUTOXYCARBONYL)-AMINO-2-[-8-AZABICYCLO[3.2.1]OCT-3-YL]-EXO-ACETATE AND ANALOGS THEREOF: KEY INTERMEDIATES FOR THE PREPARATION OF DPPIV INHIBITORS | DPP4, DPP8, DPP7 | HTR2C 3032/4885SMN1; SMN2 4071/4885NPC1 4037/4885 |
| US-12319698-B2 | Proteasome activity enhancing compounds | PSMG3, PSME3, PSMC4 | HTR2C 3675/4885SMN1; SMN2 838/4885NPC1 675/4885 |
| US-11993591-B2 | Chromen-4-one derivatives for the treatment and prophylaxis of hepatitis B virus disease | HAVCR2, CYP7A1, CYP26B1 | HTR2C 1120/4885SMN1; SMN2 2875/4885NPC1 221/4885 |
| US-20060270653-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | HTR2C 262/4885SMN1; SMN2 3349/4885NPC1 1160/4885 |
| US-20240285611-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | HTR2C 4850/4885SMN1; SMN2 3576/4885NPC1 4449/4885 |
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | HTR2C 699/4885SMN1; SMN2 1453/4885NPC1 1249/4885 |
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSME3, PSMC4 | HTR2C 3675/4885SMN1; SMN2 838/4885NPC1 675/4885 |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | BAX, BCL2, BCL3 | HTR2C 4850/4885SMN1; SMN2 3576/4885NPC1 4449/4885 |
| US-20070043023-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | HTR2C 262/4885SMN1; SMN2 3349/4885NPC1 1160/4885 |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | PTPN1, PTPN9, PTPN7 | HTR2C 3632/4885SMN1; SMN2 4144/4885NPC1 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.